New York – November 06, 2026 -- Kos Biotechnology Partners has invested in Fathom Therapeutics' oversubscribed $55 million Series A, which was led by Sutter Hill Ventures, to back a drug discovery platform that combines quantum chemistry, physics-based simulation and artificial intelligence.
Kos commits capital through its inaugural life sciences fund
The investment came through Kos BioVentures, the firm's first life sciences fund. Kos, based in New York and Athens, manages $125 million in assets. It invests across all development stages in therapeutic breakthroughs, biodefense and tech-enabled pharma services.
Microcosmos platform predicts protein-drug interactions at atomic resolution
Fathom is developing small molecule medicines on its proprietary Microcosmos platform. The platform combines physics-based simulations with AI to predict how proteins move and interact with drug molecules at atomic resolution. Kos Managing Partner Simos Simeonidis said the approach could change how medicines are found, particularly for targets long considered undruggable.
Founders include scientists behind the Anton supercomputer
Huafeng Xu, PhD, is Fathom's co-founder and CEO. Yujie Wu, PhD, serves as Chief Technology Officer, and Jesús Izaguirre, PhD, as Chief Computational Scientist. The founding team includes scientists behind the Anton supercomputer and widely adopted computational methods for predicting protein-drug interactions.
Kos targets pipeline growth and partnerships
Kos Managing Partner Alex Tzoukas said the platform has already shown compelling early results. He said Kos expects to support Fathom as it scales the platform, advances its internal pipeline and expands strategic partnerships. The source discloses no individual investment amounts, valuation or clinical timelines.